Thyas has signed a license agreement with iPS Academia Japan, Inc. (“iPS-AJ”; Sakyo-ku, Kyoto) in which iPS-AJ grants Thyas a non-exclusive license of the patents relating to iPS cell reprogramming technologies and an exclusive license of the patents relating to iPSC-to-T cell differentiation technologies applicable to the autologous iPSC-derived T cell therapies for treatments of antigen-specific tumors and infectious diseases worldwide.

iPS-AJ is a technology licensing organization of Kyoto University.